Dihydrolipoyl dehydrogenase Antibody

What is Dihydrolipoyl dehydrogenase and why is it important in research?

Dihydrolipoyl dehydrogenase (DLD) is a flavin-dependent enzyme located in mitochondrial inner membranes. It functions as the E3 component of several critical enzyme complexes, including pyruvate dehydrogenase (PDH), α-ketoglutarate dehydrogenase, and branched-chain α-ketone dehydrogenase. DLD catalyzes the oxidation of dihydrolipoamide to form lipoamide while generating NADH, making it crucial for cellular energy metabolism. Its involvement in multiple myeloma (MM) sensitivity to proteasome inhibitors has made it an increasingly important research target in cancer biology and therapeutic development .

What alternative names should researchers be aware of when searching for DLD antibodies?

When conducting literature searches or ordering antibodies, researchers should be aware that DLD may be listed under several alternative designations: Lipoamide Dehydrogenase, E3, DLDD, DLDH, GCSL, and dihydrolipoyl dehydrogenase, mitochondrial. The protein has a molecular mass of approximately 54.2 kilodaltons. Understanding these nomenclature variations is essential for comprehensive literature searches and proper antibody selection across different suppliers .

What are the primary research applications for DLD antibodies?

DLD antibodies are utilized across multiple experimental techniques including:

• Western Blot (WB) for protein expression quantification

• Immunofluorescence (IF) for subcellular localization studies

• Immunohistochemistry (IHC) for tissue expression analysis

• Enzyme-Linked Immunosorbent Assay (ELISA) for quantitative protein detection

• Immunocytochemistry (ICC) for cellular expression patterns

• Immunoprecipitation (IP) for protein-protein interaction studies

Each application requires specific antibody validation and optimization strategies to ensure reliable results in different experimental contexts .

How should researchers select the appropriate DLD antibody for their specific application?

Antibody selection should be guided by:

• Target species reactivity: Confirm reactivity with your species of interest (human, mouse, rat, etc.)

• Application compatibility: Verify validation data for your intended application (WB, IF, IHC)

• Epitope location: Consider whether N-terminal, C-terminal, or central region targeting is appropriate

• Antibody format: Determine if monoclonal (consistent but single epitope) or polyclonal (multiple epitopes) is preferable

• Citation record: Review published literature using the antibody for your application

For mitochondrial localization studies, antibodies targeting the mature protein (Ala36-Phe509 in humans) are recommended based on validated localization data in cellular models .

What controls are essential when working with DLD antibodies?

A robust experimental design requires:

These controls help distinguish genuine DLD detection from technical artifacts, particularly important when investigating subtle changes in DLD expression or activity .

How can DLD antibodies be utilized to investigate mitochondrial function and pathologies?

DLD antibodies enable sophisticated investigations of mitochondrial biology through:

• Dual-labeling immunofluorescence: Combining DLD antibodies with other mitochondrial markers allows assessment of mitochondrial integrity, distribution, and morphology changes in response to treatments or disease states.

• Proximity ligation assays: These can detect protein-protein interactions between DLD and other components of mitochondrial enzyme complexes, revealing changes in complex assembly under various conditions.

• Chromatin immunoprecipitation (ChIP): For investigating potential non-canonical nuclear functions of DLD, particularly in transcriptional regulation related to metabolic adaptation.

• Live-cell imaging: Using fluorescently-tagged antibody fragments to track DLD dynamics in real-time during metabolic stress or therapeutic interventions.

Effective visualization of DLD typically employs counterstaining with DAPI for nuclei and requires specific localization to mitochondria with punctate cytoplasmic staining patterns as validation criteria .

What methodologies can assess DLD enzymatic activity alongside immunodetection?

Comprehensive DLD characterization combines:

• Spectrophotometric assays: Measure NAD+ reduction to NADH at 340nm, reflecting DLD enzymatic activity.

• Immunocapture activity assays: Use immobilized DLD antibodies to pull down the enzyme complex, then measure activity in controlled buffer conditions.

• Combined IHC-enzyme histochemistry: Overlay antibody detection with functional formazan deposition to visualize both protein presence and activity.

• Native gel electrophoresis: Preserve protein complexes to assess both DLD incorporation into larger assemblies and their functional integrity.

Correlating immunodetection with activity measurements provides critical insights, particularly in pathological contexts where protein presence may not reflect functional capacity .

How can DLD antibodies help investigate the relationship between DLD and proteasome inhibitor sensitivity?

Recent research has identified DLD as a molecular target of bortezomib in multiple myeloma. Researchers can employ DLD antibodies to:

• Co-immunoprecipitation studies: Detect physical interactions between bortezomib and DLD protein complexes.

• Expression correlation analyses: Evaluate DLD expression levels in patient samples and correlate with clinical responses to proteasome inhibitors.

• Resistance mechanism investigations: Compare DLD levels and localization patterns between sensitive and resistant cancer cell populations.

• Target validation experiments: Use DLD knockdown approaches with antibodies as validation tools to confirm phenotypic changes.

DLD knockdown in multiple myeloma cells decreased NADH levels, which subsequently suppressed proteasome complex assembly, resulting in decreased basal-level proteasome activity and increased sensitivity to bortezomib. This mechanistic insight suggests DLD may serve as both a biomarker and therapeutic target in cancer treatment strategies .

What methodological approaches can resolve contradictory data when studying DLD in cancer contexts?

When facing inconsistent results in DLD cancer research:

• Antibody validation panel: Use multiple antibodies targeting different DLD epitopes to confirm findings.

• Expression system verification: Compare antibody detection in recombinant systems versus endogenous expression.

• Isoform-specific analysis: Employ antibodies that can distinguish potential DLD isoforms or post-translational modifications.

• Context-dependent expression: Systematically evaluate DLD expression across different growth conditions, cell cycle phases, and differentiation states.

• Complementary detection methods: Combine antibody-based detection with mass spectrometry, enzyme activity assays, or mRNA expression analysis.

Research has shown that high DLD expression correlates with inferior prognosis in multiple myeloma patients treated with proteasome inhibitor-containing regimens, suggesting its potential value as a prognostic biomarker .

What are the most common technical challenges when using DLD antibodies and how can they be addressed?

When staining human liver tissue, optimal results have been achieved using heat-induced epitope retrieval followed by DAB (brown) visualization, resulting in specific cytoplasmic and nuclear staining in hepatocytes .

How can researchers verify the specificity of DLD antibody staining in cellular localization studies?

Verification of antibody specificity requires multiple approaches:

• Co-localization validation: Perform double-labeling with established mitochondrial markers (e.g., MitoTracker, TOM20) to confirm the expected mitochondrial localization pattern.

• siRNA/shRNA knockdown controls: Compare staining patterns between wild-type and DLD-knockdown cells, with significant signal reduction expected in knockdown cells.

• Fractionation correlation: Perform cellular fractionation followed by Western blot to confirm antibody detection in mitochondrial fractions.

• Peptide competition: Pre-incubate the antibody with immunizing peptide to block specific binding sites, which should eliminate genuine staining.

• Orthogonal detection methods: Confirm localization using fluorescent protein fusions or alternative antibodies targeting different epitopes.

For validated visualization of DLD in HeLa cells, researchers have successfully used Mouse Anti-Human DLD Monoclonal Antibody (8 μg/mL) with NorthernLights 557-conjugated secondary antibody, demonstrating specific cytoplasmic localization with a punctate pattern characteristic of mitochondrial proteins .

How are DLD antibodies contributing to understanding novel therapeutic approaches?

Recent research utilizing DLD antibodies has revealed:

• Synergistic treatment strategies: DLD inhibitor CPI-613 shows synergistic anti-multiple myeloma effects with bortezomib in both in vitro and in vivo models, suggesting potential combination therapies.

• Resistance mechanism identification: DLD antibody-based screening has helped identify its role in proteasome complex assembly and function, providing mechanistic insights into therapy resistance.

• Biomarker development: Immunohistochemical evaluation of DLD expression in patient samples correlates with clinical outcomes, potentially informing treatment selection.

• Target validation studies: Antibody-confirmed DLD knockdown demonstrates increased sensitivity to proteasome inhibitors, validating it as a therapeutic target.

These findings suggest DLD-targeting therapies might increase multiple myeloma sensitivity to proteasome inhibitors, opening new avenues for treatment of resistant disease .

What are the methodological considerations when using DLD antibodies in translational research?

Translational applications require rigorous methodology:

• Tissue-specific optimization: Antibody concentrations and staining protocols must be optimized for different tissue types, with documented successful parameters for liver tissue (5 μg/mL with heat-induced epitope retrieval) .

• Patient sample considerations: Standardized protocols for tissue collection, fixation, and processing are critical for consistent DLD detection across clinical samples.

• Quantification methods: Established semi-quantitative scoring systems or digital image analysis should be employed to objectively assess DLD expression levels.

• Clinical correlation standards: Guidelines for correlating DLD expression with clinical outcomes must include appropriate statistical analyses and validation cohorts.

• Companion diagnostic development: For therapeutic targeting, antibody-based assays require rigorous validation following regulatory guidelines.

This methodological rigor ensures reproducible results when evaluating DLD as a potential biomarker or therapeutic target across different patient populations and clinical settings .